Skip to main content

DxS and BTG to Market AstraZeneca s DNA Diagnostic Technology

NEW YORK, March 23 (GenomeWeb News) - DxS and BTG said today that they have signed an exclusive license to commercialize technology developed by AstraZeneca for the detection of SNPs and other gene mutations.

DxS and BTG said they had acquired "certain rights" to AstraZeneca's technology, and would market AstraZeneca's Amplification Refractory Mutation System (ARMS) within the diagnostic and research markets.

The technology will be targeted toward companies that offer genetic variation products and services, as well as companies that are already using ARMS as part of their in-house research activities, DxS and BTG said.

DxS, a genetic analysis services provider, will offer ARMS in addition to its own Scorpions genotyping system. Stephen Little, DxS CEO, called ARMS "an excellent fit with our current portfolio."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.